Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Hypereosinophilic Syndrome (HES) Study for Adults

Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

physician talking with male patient

 

AGE: 12+ years old
SEX AT BIRTH: All
TYPE: Interventional Study
HEALTHY PARTICIPANTS: No
CONDITION: Hypereosinophilic Syndrome (HES)
LOCATION: University Hospitals Rainbow Babies & Children’s

Learn More About This Research Study

For more information, please contact study coordinator, Erica Denallo at 440-879-4136 and leave a message or click the link to the study survey below.

Study Purpose

The purpose of this study is to see if benralizumab, given as injections under the skin, can help control HES better if it is added to available standard of care HES medications.

Who Can Participate

Participants 12 years of age or older diagnosed with Hypereosinophilic Syndrome may be eligible for this study.

I'm not a robot

Study ID